^
Association details:
| Biomarker: | DNMT3A mutation |
|---|---|
| Cancer: | Lymphoma |
| Drug: | azacitidine (DNMT inhibitor) + Istodax (romidepsin) (HDAC inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Real-world experience of combined treatment with azacitidine and romidepsin in patients with peripheral T-cell lymphoma
Published date:
07/18/2023
Excerpt:
Among 26 evaluable patients, the ORR was 76.9%, and the CRR was 53%. The median number of aza/romi cycles was 3 (range, 1-12), and the median follow-up was 8.7 months. The ORR and CRR in patients with angioimmunoblastic lymphoma and TFH-PTCL was 69.5% (16/23) and 60.8% (14/23), respectively. The ORR and CRR in patients who had mutations in TET2, IDH2, and DNMT3A (total of 9 individual patients) were 77.7% (7/9) and 44.4% (4/9), respectively.
DOI:
https://doi.org/10.1182/bloodadvances.2022009445
